The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.
The firm said it would use any net proceeds for R&D, working capital, and to potentially acquire other technologies or businesses.
Natera has focused on tapping into the average risk market for its suite of noninvasive prenatal assays, which it said is paying off.
The company's revenues were driven by sales of its Panorama NIPT and Horizon carrier screening tests.
The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.
The company said it planned to launch version 3 of Panorama this year during a conference call discussing its second quarter 2016 performance.
Test volume growth for its Panorama NIPT and Horizon carrier screening tests drove its revenues gains year over year.
The partners will work together to see whether cell-free DNA levels can be used to predict organ injury in kidney transplantation and improve clinical outcomes.
Unilabs has licensed the rights to develop, validate, and run Natera's Panorama NIPT technology out of its own laboratories.
The firm did not disclose how it intended to use the $8 million, but said that it would provide temporary working capital.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.